Skip to main content
ZHEJIANG XIANJU PHARMACEUTICAL CO., LTD. logo

ZHEJIANG XIANJU PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 002332 ISIN · CNE100000K64 LEI · 300300QUEL3PNGXI1P26 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,479 across all filing types
Latest filing 2026-06-01 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002332

About ZHEJIANG XIANJU PHARMACEUTICAL CO., LTD.

https://www.xjpharma.com

Zhejiang Xianju Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of steroid hormone drugs and related pharmaceutical products. The company maintains a comprehensive product portfolio categorized into four primary therapeutic areas: corticosteroids, sex hormones, muscle relaxants, and respiratory medications. As a prominent manufacturer in the steroid hormone sector, it produces a wide range of active pharmaceutical ingredients (APIs) and finished dosage forms, including progesterone, dexamethasone, and rocuronium bromide. The company operates integrated production facilities that adhere to international quality standards, including GMP and FDA certifications. Its business model encompasses the entire value chain from pharmaceutical intermediates to final formulations, serving both domestic and global healthcare markets through a robust supply network and a focus on technical innovation in hormonal synthesis.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 93% confidence The document is an official announcement titled “关于回购公司股份的进展公告” detailing the company’s share repurchase scheme, progress to date, regulatory references, repurchase amount, price limits, timelines, and next disclosure requirements. This corresponds to a report of the company buying back its own shares. According to the classification definitions, this is Transaction in Own Shares (Code: POS).
2026-06-01 Chinese
关于2025年年度权益分派实施后调整股份回购价格上限的公告
Transaction in Own Shares Classification · 90% confidence The document is a corporate announcement disclosing an adjustment to the company’s share repurchase price cap following the 2025 dividend distribution. It details the repurchase plan, regulatory basis for price adjustment, and calculation. This clearly falls under a transaction in the company’s own shares (share buyback), matching code POS.
2026-05-28 Chinese
关于黄体酮注射液通过一致性评价的公告
Regulatory Filings Classification · 85% confidence The document is a regulatory announcement by Zhejiang XianJu Pharmaceutical Co., Ltd. regarding the NMPA approval of its progesterone injection passing generic drug consistency evaluation. It contains no financial statements or management commentary on results, nor does it solicit votes or describe corporate governance changes. It is not a financial report but rather a routine compliance/approval notice, thus best classified as a general Regulatory Filing (RNS).
2026-05-26 Chinese
仙琚制药：2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement by Zhejiang Xianju Pharmaceutical Co., Ltd. detailing the 2025 annual equity (dividend) distribution plan, including dividend per share, record and ex-dividend dates, distribution methods, and tax treatment. This clearly matches the definition of a Notice of Dividend Amount (code DIV). It is not an annual report or financial statement, nor a proxy or management discussion, but specifically a dividend distribution notice.
2026-05-21 Chinese
关于噻托溴铵奥达特罗吸入喷雾剂药品注册申请获得受理的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by Zhejiang Xianju Pharmaceutical (stock code 002332) informing the market that its drug registration application has been accepted by the National Medical Products Administration. It is not a financial report, AGM material, or other specific category, but rather a general regulatory/compliance announcement. Fits the fallback category “Regulatory Filings” (RNS).
2026-05-20 Chinese
上海市锦天城律师事务所关于仙琚制药2025年年度股东会法律意见书
Regulatory Filings Classification · 90% confidence The document is a lawyer’s “法律意见书” (legal opinion letter) issued by a law firm on the convening, procedures, eligibility and results of the company’s 2025 annual general meeting. It is not the company’s own AGM materials or slides (AGM-R), nor is it the formal voting results announcement by the company (DVA). Instead, it is a compliance/legal opinion document submitted to regulators/shareholders. It therefore falls into the fallback category for miscellaneous regulatory filings and compliance documents: RNS.
2026-05-19 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.